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Epilepsy is a condition for which regular drug treatment is normally prescribed. We have examined tffe primary care 
prescribing rates for anti-epileptic drugs (AEDs) in a region of northern England with a population of 6.8 million. Over the 
4-year period 1992-1995 the number of AED prescription items issued rose by 15%. A third of this rise is accounted for 
by increased prescribing of the new anticonvulsants, vigabatrin, lamotrigine and gabapentin, which are primarily indicated 
for adjunct use. Prescribing of phenytoin and barbiturates fell over the same period, but this reduction was more than 
compensated for by increased prescribing of carbamazepine and sodium valproate. There were notable differences in both 
the overall volume and the choice of AEDs used in different health authority areas and these are probably attributable tothe 
influence of the local secondary-care s ctor on the therapeutic regimens adopted by general practitioners in the area. 
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INTRODUCTION 
For drugs used in the treatment of a chronic condi- 
tion, the rates of prescribing will depend on three 
main factors: the true prevalence of the condition 
in the population, the diagnostic (ascertainment) rate 
and the choice of treatment. If the relevant drugs 
are prescribed only, or principally, for this condition, 
and prevalence and ascertainment rates are reason- 
ably uniform, then prescribing may give insight into 
the variability in choice of treatment. 
Drug treatment is a standard approach in the con- 
trol of epilepsy, and the relevant drugs are only rarely 
used for treating a few other limited conditions, such 
as post-herpetic neuralgia. This study, in the north- 
ern and Yorkshire region of England (population: 
6.8 million), examines general practitioner prescrib- 
ing rates for anti-epileptic drugs (AEDs), with a view 
to determining the temporal trends in choice of drug 
treatment and the extent of variability between health 
authority areas. Absolute rates of epilepsy prevalence 
are not accurately known, however for examining 
variability in choice of treatment the key requirement 
is that rates should be relatively uniform both geo- 
graphically and across the duration of the study. 
The prevalence of epilepsy depends on its defini- 
tion. Against an agreed definition of active epilepsy 
(seizures of any type in the previous 2 years, or 
seizure-free but taking AEDs) the estimated preva- 
lence is 0.5-1% I-3 . The incidence of epilepsy is 
highest in early childhood 2, but since those who be- 
come seizure-free without drug control roughly bal- 
ance incident cases in later years, the prevalence re- 
mains similar across much of the age range. How- 
ever, the prevalence rises for those aged 65 or over. 
In the health authority areas studied this age group 
accounts for between 14.5 and 18% of the resident 
populations. Although there are gender differences in 
epilepsy prevalence, the areas are sufficiently large 
to have the same male to female population ratios. 
Ethnicity may affect true epilepsy prevalence or, be- 
cause of cultural factors, ascertainment rates. In the 
United Kingdom the impact of ethnicity on epilepsy 
ascertainment and prevalence has not been quantified. 
For active epilepsy under-ascertainment by general 
practitioners i unlikely because of the prescribing of 
drugs or the occurrence of seizures. Temporal trends 
in prevalence are also unlikely to be a major factor 
over the relatively short 4 year---duration of this 
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study. Assuming prevalence uniformity, the variabil- 
ity in per capita use of AEDs should be attributable 
to differences in treatment choice. 
METHODS 
Data 
General practitioner prescribing of anticonvulsants 
(Section 4.8.1, British National Formulary 4) and reg- 
istered patient populations for the period January 
1992 to December 1995 were extracted from Pre- 
scription Analysis and Cost (PACT) data aggregated 
at the Family Health Service Authority (FHSA) level. 
The quarterly number and cost of prescription items, 
and the quantity prescribed were obtained for each 
drug in each of the 16 authorities. Data for the quar- 
ter ending June 1995 was unavailable, and for the 
quarter ending December 1993 incomplete for Wake- 
field FHSA. These two quarters were excluded. 
Over the study period there were more than 
10,000 prescribed items for each of ten AEDs. Five 
of these drugs--phenytoin, carbamazepine, ethosux- 
imide, sodium valproate and clonazepam--were ex- 
amined individually. Phenobarbitone and primidone 
prescribing were aggregated as total barbiturate pre- 
scribing, and the three newer drugs--vigabatrin, lam- 
otrigine and gabapentin--were also aggregated. Pre- 
scriptions for methyl-phenobarbitone (2200 items in 
total) were excluded from the analysis of individual 
drugs. 
Using the number of items as a measure of prescrib- 
ing volume has drawbacks, as it takes no account of 
possible systematic variation between areas or time 
periods in the average quantity prescribed per item. 
For analysis of individual drugs this is easily over- 
come by using the total quantity prescribed in grams, 
but for aggregation purposes ome meaningful equiv- 
alence between drugs is needed. Although expressing 
quantities in terms of the defined daily dose 5 (DDD) 
is the natural choice, DDDs were not available for 
all the drugs in this study. Our approach was to de- 
fine for each drug an 'adjusted item', being the aver- 
age quantity per item (in grams) over all health dis- 
tricts and all quarters. The quantities prescribed in a 
health district each quarter were then expressed as the 
numbers of 'adjusted items' for individual drugs, and 
these units could sensibly be aggregated across drugs. 
Assuming that there was no systematic difference in 
prescription duration for primidone and phenobarbi- 
tone, the sizes of 'adjusted' items closely reflected 
the ratio of 250 mg primidone to 60 mg phenobarbi- 
tone expected on the basis of bioequivalence. For the 
newer drugs, the size of 'adjusted' items confirmed an 
equivalence, based on recommended daily doses, of 
2000 mg vigabatrin to 1200 mg gabapentin, and indi- 
cated 175 mg as an equivalent average daily quantity 
for lamotrigine. This latter quantity reflects the aver- 
age dose of lamotrigine across different herapeutic 
regimens. The advised dose 4 is 100-200 mg per day 
for monotherapy or prescribed with the enzyme in- 
hibitor sodium valproate, whereas in adjunct with an 
enzyme inducer such as carbamazepine or phenytoin 
the recommended dose is 200---400 mg per day. 
Analysis 
For prescribing volume FHSA rates were expressed 
as 'adjusted' items per 1000 registered population. In 
order to compare variability between different areas 
without confounding by temporal changes, relative 
rates were also calculated as the ratio of the FHSA 
rate to that for the region as a whole, for the same 
drug and time period. A similar procedure applied to 
analysis of cost per item. 
Variability between areas was defined in non- 
parametric terms, to avoid undue influence from ex- 
treme rates in some instances 
interquartile range 
quartile variation, qv = x 100. 
1.35 x median 
For a normal distribution, the quartile variation is 
equivalent to the coefficient of variation as usually 
defined 6. 
RESULTS 
Prescribing for the region as a whole 
The overall volume of prescribing rose steadily 
over the 4-year period, from 26 to 30 AED items 
per 1000 patients per quarter. For carbamazepine 
items (8.6-10.7), valproate (5.0-6.6) and vigaba- 
trin/lamotrigine/gabapentin (0.41-1.82) the quarterly 
rates per 1000 patients all rose; prescribing for 
both clonazepam (0.82) and ethosuximide (0.16) was 
static; and for phenytoin (7.6-7.2) and phenobarbi- 
tone/primidone (3.4-2.7) the rates fell (Fig. 1). For 
individual drugs, there were no significant changes 
over the 4-year period in the average quantity per 
prescription item: phenytoin 8.85 g, carbamazepine 
18 g, valproate 34.3 g, clonazepam 59 mg, ethosux- 
imide 25 g, phenobarbitone 3.00 g, primidone 24.7 g, 
lamotrigine 5.5 g, vigabatrin 63 g, gabapentin 38.5 g. 
Consequently volume trends are the same whether ex- 
pressed in items or grams. The above quantities per 
item were used to define the size of an 'adjusted' 
item. 
Differences between FHSAs 
In the following inter-FHSA comparisons all rates are 
on the basis of 'adjusted' items per 1000 population. 
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Fig. 1 : NYRHA prescribing of anti-epileptic drugs (BNF 4.8.1 ). o, phenytoin; o, valproate; • - - •, phenobarbitone/primidone; • - - . ,  
vigabatrin/lamotrigine/gabapentin; A, clonazepam;., carbamazepine; +, ethosuximide. 
Table 1: Anticonvulsant prescribing for quarter ending March 1992. Regional per capita rate and relative rates for FHSAs, with the 
four highest and the four lowest rankings indicated (except ethosuximide for which rates and ranks were highly variable between 
quarters) 
Vigabatrin. 
Total anti- Phenobarbitone lamotrigine 
convulsants Phenytoin and primidone Carbamazepine Valproate Clonazepam and gabapentin Ethosuximide 
Regional rate: 
"adusted' items/1000 
patients/quarter 25.95 7.61 3.38 8.63 4.95 0.82 0.41 0.16 
lnter-FHSA 
quartile variation (%) 7.6 16.5 15.5 8.7 8.3 35.8 26.6 21.9 
FHSA relative rates (rank) 
Newcastle 1.15 (1) 1.34 (2) 1.13 (21 1.14 (2) 0.89 (151 0.95 1.93 (1) 0.79 (13) 
Gateshead 1.14 (2) 1.35 (1) 1.10 (4) 1.09 (3) 0.96 1.05 1.09 0.93 
Durham 1.09 (3) 1.13 1.01 1.04 1.04 1.85 (I) 1.12 0.67 (14) 
N Tyneside 1.09 (4) 1.25 (3) I.I1 (3) 1.06 0.96 0.75 0.80 0.41 (16) 
Northumberland 1.07 1.18 (4) 1.05 1.04 0.98 0.72 (14) 1.16 (4) 1.52 (1) 
Cleveland 1.06 0.93 (13) 0.91 1.27 (I) 0.95 1.31 (4) 1.38 (2) 1.08 
Sunderland 1.06 0.98 1.08 0.96 1.31 (2) 1.56 (2) 0.65 (16) 0.99 
S Tyneside 1.03 1.18 0.90 1.02 0.99 0.73 (13) 1.09 0.58 (15) 
Calderdale 1.01 1.01 0.90 0.85 (15) 1.37 (I) 1.04 0.98 1.19 (2) 
Wakefield 1.00 1.02 0.84 (15) 1.07 0.92 (13) 1.32 (3) 0.84 I. I 1 
Cumbria 0.99 1.03 0.95 0.95 (13) 1.05 (4) 0.87 0.71 (15) 1.08 
Leeds 0.98 0.97 0.87 (131 1.08 (4) 0.87 (16) 0.97 1.21 (3) 1.16 (3) 
Humberside 0.96 (131 1.10 1.43 (I) 0.71 (16) 0.91 (14) 0.75 0.76 (13) 0.98 
N Yorkshire 0.94 (14) 0.83 (14) 0.84 (14) 1.06 1.02 0.70 (15) 0.76 (14) 1.10 
Kirklees 0.89 (151 0.74 (15) 1.06 0.87 (14) 1.08 (3) 0.78 0.80 1.13 (4) 
Bradford 0.82 (16) 0.57 (16) 0.67 (16) 0.97 1.04 0.63 (16) 1.01 0.85 
Relative to the region as a whole, FHSA rates for total 
AED prescribing changed little over the study period. 
The rates for the first and last quarters of the study pe- 
riod are shown in Tables 1 and 2 respectively. The ex- 
tremes were Newcastle prescribing 115-118% of the 
regional per capita rate, and Bradford where relative 
prescribing rose from around 80% in the period up to 
September 1993 to around 85% over the remaining 
period. Inter-FHSA variability, as measured by quar- 
tile variation, increased slightly from 8 to 14%. 
Tables 1 and 2 also show the FHSA relative rates 
for prescribing of individual drugs, and the regional 
per capita rates. The quartile variation gives a sum- 
mary measure of the variability between FHSAs, 
and the ranks of the highest four and lowest four 
FHSAs highlight the more extreme relative rates. In 
general, both the relative rates and the quartile vari- 
ation showed surprising consistency over the 4-year 
period. 
Bradford (--~ 60%), Kirklees (~ 70%) and North 
Yorkshire (83% falling to 75%) were distinctly low 
users of phenytoin, with the other FHSAs more 
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closely grouped. For the barbiturates, phenobarbi- 
tone and primidone, Bradford again had the lowest 
usage (65-70%), and Humberside rates were much 
higher than elsewhere (143% falling to 132%). Of 
the three FHSAs with low (-,~ 80%) carbamazepine 
prescribing in December 1995, Humberside had risen 
from 71% over the study period, whilst Kirklees and 
Calderdale had declined slightly from 85%. Through- 
out the 4 years, relative usage of carbamazepine was 
highest in Cleveland, though the gap between it and 
the majority of FHSAs closed considerably in the 
latter half of 1995, as usage elsewhere increased 
more rapidly. Valproate prescribing was high in both 
Sunderland and Calderdale throughout the 4 years, 
whereas in Durham usage rose faster than for the re- 
gion as a whole during the last 18 months. There was 
wide variation between FHSAs in clonazepam usage 
particularly during the earlier years of the study, and 
Durham and Sunderland continued to have very high 
relative rates (160% in December 1995). 
In early 1992 Newcastle usage of the three newer 
drugs (vigabatrin, lamotrigine, gabapentin) was dis- 
tinctly higher than elsewhere but still small in abso- 
lute terms--250 items per quarter, principally viga- 
batrin. Because of the small volume of prescribing, 
relative rates were very unstable in the early period of 
the study. The most notable change was in Humber- 
side where the relative rate rose from 85% in June 
1993 to 120% (highest FHSA) in December 1995. 
Newcastle and North Tyneside were high users of vi- 
gabatrin, whereas in Leeds and Humberside the high 
rates derived from lamotrigine use. 
Prescribing of ethosuximide was low and conse- 
quently relative rates varied greatly from quarter to 
quarter for individual FHSAs. 
Newer drugs 
Gabapentin only came into use in the quarter end- 
ing June 1993, whereas lamotrigine was prescribed 
by general practitioners in the region from late 1991, 
and vigabatrin from 1989. The regional usage of these 
drugs, for a near-static population, is illustrated in 
Fig. 2. On the logarithmic scale used, parallel gra- 
dients indicate equal percentage growth. After steep 
rises for lamotrigine and gabapentin following their 
initial introduction, growth rates had steadied at 10 
and 8% per quarter espectively by December 1995. 
However, the volume of lamotrigine (7408 items per 
quarter) was far higher than for gabapentin (2091 
items). Prescribing for vigabatrin grew at the lower 
rate of around 2% per quarter throughout the study 
period, with the quarterly number of items overtaken 
by lamotrigine in June 1993. 
Prescribing costs 
The various AEDs have wide-ranging unit costs (per 
daily dose) so differences between FHSAs in over- 
all costs per prescription item are largely determined 
by the differences in drug mix. For individual drugs 
inter-FHSA variability in cost per item is influenced 
by the differences between FHSAs in the average 
quantities prescribed per item. For example, an av- 
erage prescription for carbamazepine was 20.2 g in 
Cleveland but only 15.5 g in Newcastle. Examination 
of cost per gram within individual drugs revealed lit- 
tle inter-FHSA variation except for clonazepam. This 
high variability for clonazepam was due to the use of 
very expensive special preparations (typically £35 per 
item instead of £3.70, at 1995 prices) by a few prac- 
tices particularly in Sunderland but also, to a lesser 
extent, in Northumberland and Gateshead. In Decem- 
ber 1995 the average cost of clonazepam items in 
Sunderland was nearly three times the average cost 
regionally. 
DISCUSSION 
In the present study we have not attempted to de- 
fine the prevalence of epilepsy, but have examined 
prescribing of AEDs across 16 health authority areas 
over a 4-year period. Although the choice of AED 
will depend on the type of epilepsy, we have no rea- 
son to believe that the proportions of each type differ 
across the 16 areas. During this time prescribing vol- 
ume increased by 15% (3.8% per annum). Possible 
reasons for this change include: greater use of more 
than one drug concurrently; a reduction in the number 
of patients with active epilepsy who are not using any 
AEDs; or increasing concerns about stopping med- 
ication in patients who have been seizure free. In 
the Mersey Health Region during the early 1990s an 
audit 7 of 31 practices identified 1341 patients (0.8%) 
with active epilepsy of whom 110 were not receiving 
AEDs, and 69% of the rest were on monotherapy. 
Another audit 8 of 25 general practices in Glasgow 
reported that 1052 (0.72%) of 145,609 patients were 
prescribed AEDs and of these 76% were prescribed 
one drug only. In our study, one-third of the observed 
15% increase in AED prescribing is accounted for 
by increased usage of the three newer drugs, and in 
general these are used in adjunct with other drugs; 
only lamotrigine is currently licensed as monotherapy 
for epilepsy. Thus some of the increased usage may 
be attributable to polytherapy involving these drugs 
rather than additional patients being treated, espe- 
cially as it is recognized that a significant proportion 
of epileptics have disease which is difficult to control. 
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Table 2: Anticonvulsant prescribing for quarter ending December 1995. Regional per capita rate and FHSA relative rates with the 
four highest and the four lowest rankings indicated (except ethosuximide for which rates and ranks were highly variable between 
quarters) 
Vigabatdn, 
Total anti- Phenobarbitone lamotrigine 
convulsants Phenytoin and primidone Carbamazepine Valproate Clonazepam and gabapentin Ethosuximide 
Regional rate: 
'adusted" items/lO00 
patients/quarter 30.04 
lnter-FHSA 
quartile variation (%) 14.2 
FHSA relative rates (rank) 
Newcastle I. 18 ( 1 ) 
Gateshead I. 15 (3) 
Durham 1.14 (45 
N Tyneside 1.15 (2) 
Northumberland 1.09 
Cleveland I. l0 
Sunderland I. 12 
S Tyneside 1.03 
Calderdale 0.95 
Wakefield 1,00 
Cumbria 1.01 
Leeds 0.92 (13) 
Humberside 0.97 
N Yorkshire 0,88 (14) 
Kirklees 0,83 ( 161 
Bradford 0.84 ( 151 
7.19 2.72 10.69 6.63 0.82 1.82 0.16 
21.2 20.3 13.8 8.3 26.7 16.4 28.2 
1.36 (2) 1.18 (3) 1.15 (35 1.06 (4) 1.09 1.14 (35 1.39 (35 
1.37 (I) 1.14 1.14 (4) 0.99 1.04 0.98 0.79 (15) 
1.17 1.06 l , l l  1.17 (3) 1.60 (I) 0.96 0.80 (14) 
1.33 (3) 1.20 (25 1.19 (2) 0.92 (14) 0.83 1.14 (4) 1.03 
1.22 1.13 1.12 0.95 0.80 1.00 1.41 (2) 
1.00 0.96 1.23 (15 1.00 1.17 (4) 1.18 (2) 1.10 
1.08 1.15 (4) 1.05 1.26 (2) 1.59 (2) 1.01 0.83 
1.25 (4) 0.89 1.02 0.94 (13) 0.69 (14) 0.91 0.82 (13) 
0.92 (131 0.88 0.81 (14) 1.27 (11 0.93 0.83 (155 1.30 (4) 
1.13 0.82 (14) 1.05 0,87 (15) 1.25 (35 0.89 (13) 0.98 
l, l0 1.07 0.96 0.96 1.08 0.98 1.43 ( 1 ) 
0.92 0.85 (13) 0.97 0.81 (161 1.03 1.10 0.96 
1.01 1.32 ( I ) 0.78 (16) 1.05 0.72 (135 1.20 ( I ) 0.85 
0.75 (14) 0.80 (155 0.96 (131 0.97 0.69 (151 0.84 (14) 0.98 
0.69 (155 0.98 0.78 (15) 0.95 1.05 0.91 0.98 
0,58 (165 0.66 (161 1.02 0.98 0.62 (165 0.69 (161 0.73 (161 
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Fig. 2: Primary care prescribing of new anti-epileptic drugs in the region, o, vigabatrin (introduced 12/89); e, lamotrigine 
(introduced 12/91); A, gabapentin (introduced 6/93). 
Although barbiturate and phenytoin usage declined 
over the period (down 20 and 5% respectively), this 
is more than outweighed by increased prescribing for 
carbamazepine (up 24%) and sodium valproate (up 
33%). There may have been an increase in the num- 
ber of patients being prescribed AEDs, either through 
increased ascertainment or because they remain on 
therapy longer despite having become seizure free. 
However, the rise in AED usage may arise because, 
despite reports of previous trends towards a reduction 
in polytherapy 9, the adjunct use of the newer drugs 
is viewed by prescribers as legitimizing polytherapy 
more broadly. 
Individual health authorities showed considerable 
differences both in the overall volume of prescribing 
and in their usage of individual drugs. This suggests 
that preferences in the secondary care sector, or possi- 
bly local treatment guidelines, may generate common 
influence on the choice of therapy provided in local 
practices. In some geographical areas prescribing 
is low only for specific drugs whereas in others low 
prescribing applies more generally. For example, car- 
bamazepine prescribing is low in Kirklees, Calderdale 
and Humberside, but in Calderdale this is compen- 
sated for by high valproate usage and in Humberside 
by barbiturate prescribing. Usage of phenytoin is par- 
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ticularly low in Bradford, and since the population 
age breakdown is similar in Cleveland and Sunder- 
land cannot be explained on these grounds. Kirklees 
and Bradford also have low AED prescribing en- 
erally. Cultural differences between ethnic groups 
may underlie some of this variation in AED prescrib- 
ing. At the 1991 census the Asian population was 
13.6% in Bradford and 8.2% in Kirklees, 3.9% in 
Calderdale, 3.3% in Leeds, 2.9% in Newcastle, !.4% 
in Cleveland, I% in Wakefield and less than 0.75% 
in the other health areas. 
New drugs were taken up earlier in the teaching 
hospital health districts of Newcastle and Leeds. In 
Newcastle vigabatrin was used earlier than elsewhere, 
and in Leeds lamotrigine. A likely reason is the in- 
fluence of neurologists in teaching hospitals in these 
health districts, and may be a consequence of lo- 
cal clinical trials. The relatively late uptake of these 
newer drugs in Humberside, and the particularly high 
phenobarbitone usage, may also be attributable to lo- 
cal opinion at the time of the study. Both Durham and 
Sunderland had higher than average prescribing for 
both valproate and clonazepam, with usage of other 
drugs running near, or slightly above, the rates for 
the region as a whole. This could well reflect the in- 
fluence of local specialists. 
The benzodiazepine anticonvulsant clonazepam 
shows the largest variability between health districts, 
with usage in Durham well over twice that in Brad- 
ford. However, the absolute quantities prescribed are 
still lower than for all AEDs except ethosuximide. 
Again this is likely to be due to local secondary care 
influences. 
There is less apparent variability in the prescrib- 
ing of AEDs by comparison with some other drugs 
we have investigated. For example, inter-FHSA quar- 
tile variation for H2 blockers, beta-blockers, ACE in- 
hibitors and inhaled bronchodilators i between 18 
and 32%, and for oral antidiabetics, HRT, and in- 
haled steroids, which have more clearly defined in- 
dications for use, quartile variation is in the range 
I0-16% (unpublished work). None the less it is ev- 
ident that epilepsy management is by no means uni- 
form. This lends support to comments made else- 
where about quality of epilepsy care in the United 
Kingdom I°. We believe that examining prescribing 
data of this type can be of value in assessing the role 
of drugs in the treatment of epilepsy within the pri- 
mary care sector. It also raises important questions 
about the variability of management approach to this 
common disabling condition by hospital consultants 
in different areas, and suggests that agreed clinical 
guidelines for epilepsy would have a useful role. 
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